Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab for COVID-19 Infection
NCT04494724Phase 2Unknown
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2020
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of clazakizumab in coronavirus disease 2019 (COVID-19), sponsored by Houston Methodist Research Institute. Status: unknown.
02
Drugs
clazakizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04494724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04494724.